Plaque Psoriasis

Rates of adverse events leading to discontinuation were similar between populations of moderate-to-severe psoriasis and psoriatic arthritis.

These data on the efficacy of bimekizumab suggest positive therapeutic effects on nail, scalp, and genital lesions as well as quality of life.

This analysis suggests additional support may be required for tildrakizumab-associated adverse drug reactions, given these new insights.

These data suggest that physical activity interventions can lead to visible improvements in PASI scores after 20 weeks of implementation, as well as cardiometabolic improvements.

In this analysis, the biggest predictors of biologic initiation among individuals with diagnoses of psoriasis were evaluated.

These data suggest benefits to pregnant mothers with this condition following early biologic intervention, with treatment leading to rapid refractory pustular psoriasis remission.

These data point to differences between genders such as time to initiation of treatment, treatment choice, response to medication, adverse events, and adherence.

New study highlights racial disparities in psoriasis management, revealing non-Hispanic Black patients are twice as likely to receive a skin biopsy compared to White counterparts.

This analysis represents the first to indicate that extending guselkumab can lead to disease activity control among those with early complete skin clearance.

This interview segment involved a discussion with Gooderham regarding the implications of recent clinical trial findings for patients with scalp and body psoriasis.

In this interview, Gooderham highlights the ARRECTOR study findings which led to roflumilast foam’s supplemental new drug application to the FDA.

These data highlight gender differences related to dysmorphic concern and the prevalence of body dysmorphic disorder among those with various dermatologic disorders.

This supplemental new drug application for once-daily roflumilast foam follows positive results of the ARRECTOR phase 3 study.

These findings represent the first comprehensive research into the greater frequency of APS autoantibodies linked with treating psoriasis with TNF inhibitors.

In this exclusive deep dive, a pair of leading dermatologists highlight the new data defining ruxotitinib cream, upadacitinib, and more agents from the revolutionary drug class.

These data suggest that the introduction of the concept of circadian syndrome contributes to greater understanding of risk management for those with psoriasis.

These data highlight results on efficacy, quality of life, and tolerability of DMF within routine clinical practice among those with plaque psoriasis.

These data suggest that risk of developing psoriatic arthritis among patients with different variants of psoriasis vary based on race and sex as well.

A study with real-world data showed certolizumab pegol was effective in treating psoriasis a year later, with a probability of 1-year persistence at approximately 85%.

Awareness of these data may allow for dermatologists to better care for patients with anogenital pruritus as well as their families.

This analysis was done to verify the hypothesis that psoriatic arthritis is primarily genetically predetermined and distinct from the condition of psoriasis.

These findings highlight clinician versus patient perceptions of chronic pruritus assessment using patient-reported outcome measures.

Individuals with both psoriasis and hypertension have approximately a 2-fold increased mortality risk, which is greater than the mortality risk for psoriasis or hypertension alone.

These data highlight the association between risk of developing polyneuropathy and the presence of psoriasis and psoriatic arthritis.

In this analysis, the investigators looked at the impacts of the IL-23 inhibitor guselkumab on patients with psoriasis.